Atossa Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group maintained a Buy rating on the stock and has a $4.00 price target.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Jason McCarthy has given his Buy rating due to a combination of factors surrounding Atossa Therapeutics’ strategic advancements in breast cancer treatment. The company’s focus on the low-dose endoxifen program for breast cancer risk reduction is a significant near-term priority, with the potential for an NDA filing contingent on forthcoming feedback from the FDA. A favorable outcome from this interaction could serve as a crucial catalyst for the company’s stock.
Additionally, Atossa is progressing with its high-dose endoxifen program targeting metastatic ER+/HER2– breast cancer, with plans to file an IND by the end of 2025. This initiative is poised to assess the safety and efficacy of endoxifen, which has shown promise in achieving therapeutic levels more rapidly than the current standard of care, tamoxifen. These developments, coupled with the company’s robust cash position, underpin McCarthy’s optimistic outlook and Buy rating.
McCarthy covers the Healthcare sector, focusing on stocks such as SCYNEXIS, OS Therapies Incorporated, and Neuphoria Therapeutics. According to TipRanks, McCarthy has an average return of -14.4% and a 33.20% success rate on recommended stocks.